aTyr Pharma, Inc.(US:ATYR) Businesswire·2025-12-08 18:36Core Viewpoint - aTyr Pharma, Inc. is facing a federal securities class action lawsuit due to allegations of making false and misleading statements regarding the efficacy of its drug Efzofitimod, which led to artificially inflated stock prices [1][2]. Group 1: Allegations and Impact - The complaint claims that aTyr Pharma and its executives provided overly positive statements while concealing material adverse facts about Efzofitimod's effectiveness, particularly its ability to allow patients to taper off steroid usage completely [2]. - In the EFZO-FIT study, efzofitimod did not demonstrate a significant change in mean daily oral corticosteroid (OCS) dose at week 48, with a reduction of 2.79 mg for the drug compared to 3.52 mg for placebo. Complete steroid withdrawal was achieved in 52.6% of patients treated with efzofitimod versus 40.2% on placebo [3]. - Following the release of the study results, aTyr Pharma's stock plummeted by 83.25%, dropping from a market close of $6.03 on September 12 to $1.01 on September 15 [3]. Group 2: Legal Proceedings - The deadline for investors to seek the role of lead plaintiff in the class action is December 8, 2025. The lead plaintiff is defined as the investor with the largest financial interest who directs the litigation on behalf of the class [1][4]. - Any member of the putative class can move the court to serve as lead plaintiff or choose to remain an absent class member, with no impact on their ability to share in any recovery [4]. Group 3: Additional Information - Faruqi & Faruqi, LLP is encouraging individuals with information regarding aTyr's conduct, including whistleblowers and former employees, to come forward [5]. - For more details about the class action, interested parties can visit the law firm's website or contact them directly [6].